Harmony Biosciences Holdings, Inc. 8K

Harmony Biosciences provided Q2 2026 results showing record WAKIX revenue and reaffirmed 2026 guidance while outlining pipeline, IP protection, and business development plans supported by a strong balance sheet.

Harmony Biosciences filed a Form 8-K to furnish its Q2 2026 financial results and business update, reporting record quarterly net product revenue of $261.3 million for WAKIX (up 30% year over year) and strong profitability and cash generation, reiterating its 2026 net revenue guidance of $1.00–$1.04 billion, highlighting progress on its BP-205 orexin-2 receptor agonist program with encouraging Phase 1 SAD data and plans for MAD data and Phase 1b/2 studies, updating on multiple late-stage and next‑generation pitolisant and epilepsy programs with key data and PDUFA milestones concentrated in 2027–2028, and emphasizing its IP and patent litigation strategy to protect the pitolisant franchise along with a business development focus supported by approximately $963 million in cash.

Filing Facts

CIK

1802665

Ticker

HRMY

Form

8K

Source Type

fda

Accession

0001104659-26-090086

Alert Tier

6